Ovation has acquired the commercial rights to Xenazine (tetrabenazine tablets) from Prestwick for the treatment of chorea associated with Huntington’s disease (HD).

Xenazine, a monoamine depletor, is expected to be available by the end of the year in 12.5mg and 25mg dosage strengths.

For more information call (847) 282-1000 or visit www.ovationpharma.com.